Neogen Net Total Equity Issued/Repurchased 2010-2025 | NEOG
Neogen net total equity issued/repurchased from 2010 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
| Neogen Annual Net Total Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $2 |
| 2023 | $1 |
| 2022 | $8 |
| 2021 | $35 |
| 2020 | $29 |
| 2019 | $14 |
| 2018 | $23 |
| 2017 | $21 |
| 2016 | $12 |
| 2015 | $9 |
| 2014 | $15 |
| 2013 | $10 |
| 2012 | $6 |
| 2011 | $10 |
| 2010 | $6 |
| 2009 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $1.118B | $0.924B |
| Neogen Corp. develops and markets food and animal safety products. Its Food Safety Division markets culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen has 2 business segments: Food Safety and Animal Safety. Food Safety: The products in the segment include tests for Mycotoxins, Food allergens, Dairy antibiotics, Foodborne pathogens, Spoilage microorganisms, Sanitation monitoring, Dehydrated culture media and Seafood contaminants. Animal Safety: The division is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the worldwide animal safety market. These products are marketed via national & international distributors and farm supply retail chains in the U.S. and Canada. It acquired Delta Genomics Centre in Canada. | |||